The vial arrives as a white powder. You mix it with special water at the kitchen counter and inject it. The label says for research use only, or not for human consumption. And the company that shipped it may have been indicted for feeding fentanyl ingredients to Mexican cartels. That is the gray-market peptide trade the Journal mapped on Saturday, Oct. 17.
Patricia Kowsmann and Sara Ashley O'Brien report that Chinese chemical makers who sold fentanyl precursors have found a new U.S. market. TRM Labs, which traces crypto payments, has tracked more than 200 companies that sold those precursors. At least 50 of them now sell peptides, and the number is growing. The products promise a tan, tissue repair or weight loss. The ads promise rigorous quality control. They don't mention the indictments.
One of them, Anhui Rencheng Technology, was indicted by the Justice Department in 2023 for supplying precursors used by Mexican cartels. Its website now sells Melanotan II, a tanning peptide, and semaglutide, the active ingredient in Ozempic, in salt form. It didn't reply to the Journal. The money has moved fast. Before 2025, the gray-market peptide trade averaged about $200,000 a month in purchases, by Chainalysis's count. This year crypto purchases have topped $10 million a month.
What a peptide is, and what it has come to mean
Peptides are chains of amino acids. The word covers approved drugs like insulin and Ozempic. Online it has come to mean injectables the FDA never approved. Influencers, podcasters and alternative-medicine doctors endorse them, and so has the health secretary. Med spas and telehealth firms supply some. Many Americans just order from a website. Some buyers told the Journal they picked Chinese sellers because they were cheaper. An HHS spokesperson said the FDA "is concerned about the sale of unapproved drug products." Shabbir Imber Safdar of the Partnership for Safe Medicines says people "don't appreciate the safety provided by the FDA" system. Because they don't see the risk, he says, they walk away from that protection blind.
Our read
Our read is Consumer Protection (M11) and Health Costs. The verdict is AVOID, as a general safety principle and not medical advice. A cheap vial of semaglutide salt from a precursor factory is no bargain on a GLP-1. It's an unapproved drug from a seller with no inspector, no recall system and no one to call when the dose is wrong. The savings show up now. The bill, if it comes, shows up in an emergency room. The price gap is the whole sell. The story doesn't name Ozempic's maker, Novo Nordisk (NVO). It's held at weight in 11 of our model books, and nothing was added.
The check for your own plan is in your health-insurance folder. If a GLP-1 is on your list, price the approved version through your plan's drug list and the maker's own savings program before you price anything online. Coverage often depends on why the drug is prescribed. Then check your deductible. A bootleg vial never counts toward it, and an approved drug through your plan may. Pull up the drug list this week, before an influencer does your shopping. Buying the umbrella from a stranger in the rain is how you end up wet anyway. A quick look at what your plan actually covers is the dry-day move.